ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion: new indication

Obinutuzumab (Gazyvaro)

Gazyvaro is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE) despite standard therapy.

CHMP opinion 12 Nov 2026 · Roche Registration GmbH

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.